These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33969261)

  • 1. Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry.
    Beyer-Westendorf J; Marten S; Tittl L; Naue C; Bornhäuser M
    TH Open; 2021 Apr; 5(2):e143-e151. PubMed ID: 33969261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.
    Keller L; Marten S; Hecker J; Sahin K; Tittl L; Beyer-Westendorf J
    Int J Cardiol; 2018 Apr; 257():276-282. PubMed ID: 29506708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term VTE treatment with rivaroxaban: Results from the DRESDEN NOAC REGISTRY.
    Marten S; Naue C; Tittl L; Bornhauser M; Beyer-Westendorf J
    Thromb Res; 2021 Dec; 208():181-189. PubMed ID: 34808410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry.
    Müller S; Tittl L; Speed V; Roberts L; Patel J; Patel R; Arya R; Kucher N; Spirk D; Sahin K; Beyer-Westendorf J
    Res Pract Thromb Haemost; 2022 Oct; 6(7):e12829. PubMed ID: 36324830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice.
    Hendriks SV; Klok FA; Stenger WJE; Mairuhu ATA; Eikenboom J; Fogteloo J; Huisman MV
    TH Open; 2020 Apr; 4(2):e119-e126. PubMed ID: 32607465
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
    Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT
    Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Effectiveness and Safety of Apixaban versus Warfarin in Patients with Acute Venous Thromboembolism: Experience of a Large Tertiary Hospital in Saudi Arabia.
    Al Yami MS; Alzahrani MY; Alshehri AM; Alshaya OA; Alsubiae NS; Alharbi YM; Albaiahy LK; Aldeiban M; Alkuait HA; Alobaidi W; Aldawsari A; Almutairi NM; Alshibani M; Korayem GB; Alfayez OM; Almutairi AR; Almohammed OA
    Int J Gen Med; 2021; 14():4031-4037. PubMed ID: 34349553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism.
    Kang N; Sobieraj DM
    Thromb Res; 2014 Jun; 133(6):1145-51. PubMed ID: 24713109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.
    Helmert S; Marten S; Mizera H; Reitter A; Sahin K; Tittl L; Beyer-Westendorf J
    J Thromb Thrombolysis; 2017 Aug; 44(2):169-178. PubMed ID: 28643004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
    J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
    Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
    Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
    Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
    Sobieraj DM; Coleman CI; Pasupuleti V; Deshpande A; Kaw R; Hernandez AV
    Thromb Res; 2015 May; 135(5):888-96. PubMed ID: 25795564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
    de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
    Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.